| Intervention(s) and comparator(s) | Age [mean years (SD)] | Height [mean cm (SD)] | Comedications/Cointerventions | Comorbidities | |
| Hero 2005 | I: letrozole | 11 (1.7) | 128.5 (6.9) | Nil | 4 on ICS |
| C: placebo | 11 (1.5) | 127.7 (6.6) | Nil | 2 on ICS | |
| Mauras 2008 | I: anastrozole + GH | 13.8 (0.3) | 149.7 (1.6) | GH | ‐ |
| C: placebo + GH | 14.2 (0.2) | 151.6 (1.3) | GH | ‐ | |
| Salehpour 2010 | I1: letrozole | 13.6 (0.8) | ‐ | Nil | ‐ |
| I2: oxandrolone | 13.7 (0.9) | Nil | ‐ | ||
| C: placebo | 13.5 (0.9) | Nil | ‐ | ||
| Wickman 2001 | I: letrozole + testosterone | 15.2 (0.8) | 155.3 (6.7) | Testosterone | ‐ |
| C1: placebo + testosterone | 15 (0.8) | 151.9 (8.3) | Testosterone | ‐ | |
| C2: no treatment | 15 (0.7) | 154.3 (4.4) | Nil | ‐ | |
| "‐" denotes not reported GH: growth hormone; ICS: inhaled corticosteroids; SD: standard deviation | |||||
Official websites use .gov
A
.gov website belongs to an official
government organization in the United States.
Secure .gov websites use HTTPS
A lock (
) or https:// means you've safely
connected to the .gov website. Share sensitive
information only on official, secure websites.